New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCardiogen vs Larazotide Acetate

Cardiogen vs Larazotide Acetate

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cardiogen
Recovery & Repair
Larazotide Acetate
Summary
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
Half-Life
Short (minutes); gene-regulatory effects persist longer
Local gut action; minimal systemic exposure
Admin Route
SubQ, Oral
Oral
Research
Typical Dose
10 mg per day
0.5-2 mg
Frequency
Daily for 10–30 days
3x daily
Key Benefits
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
  • Directly reduces intestinal tight junction permeability
  • Clinical efficacy in celiac disease (Phase 3 trials)
  • Reduces systemic inflammation from gut permeability
  • Targets root cause of leaky gut (Zonulin pathway)
  • Local gut action without systemic absorption
  • Potential application in IBS, IBD, autoimmune conditions
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
  • Headache (mild, dose-dependent)
  • Nausea (rare)
  • Well-tolerated overall in clinical trials
Stacks With